Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Change in Accured Expenses (2024 - 2025)

Historic Change in Accured Expenses for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to $3.3 million.

  • Xilio Therapeutics' Change in Accured Expenses rose 166966.82% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$945000.0, marking a year-over-year change of. This contributed to the annual value of -$496000.0 for FY2024, which is 38342.86% down from last year.
  • Per Xilio Therapeutics' latest filing, its Change in Accured Expenses stood at $3.3 million for Q3 2025, which was up 166966.82% from $879000.0 recorded in Q2 2025.
  • Xilio Therapeutics' Change in Accured Expenses' 5-year high stood at $3.3 million during Q3 2025, with a 5-year trough of -$6.1 million in Q1 2025.